Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
暂无分享,去创建一个
M. Shahin | Wei Hu | J. Fiorica | H. Lankes | R. Mannel | R. Schilder | H. Pathak | William E. Brady | Xun C. Zhou | R. Katherine Alpaugh | Anil K. Sood | Andrew K. Godwin